BBLG
Bone Biologics Corp
$
2.345
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.390
Open
2.340
VWAP
2.33
Vol
16.20K
Mkt Cap
3.76M
Low
2.2965
Amount
37.78K
EV/EBITDA(TTM)
--
Total Shares
1.10M
EV
1.01M
EV/OCF(TTM)
--
P/S(TTM)
--
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2025Q1
FY2025Q2
--
--
-3.600
-26.23%
--
--
-2.880
-63.36%
--
--
-0.580
-85.57%
Estimates Revision
The market is revising No Change the revenue expectations for Bone Biologics Corporation (BBLG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -49.57%.
EPS Estimates for FY2025
Revise Downward
-73.63%
In Past 3 Month
Stock Price
Go Down
-49.57%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Bone Biologics Corp (BBLG.O) is -1.24, compared to its 5-year average forward P/E of -4.90. For a more detailed relative valuation and DCF analysis to assess Bone Biologics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.90
Current PE
-1.24
Overvalued PE
5.74
Undervalued PE
-15.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+14.94%
-1.04M
Operating Profit
FY2025Q1
YoY :
+17.45%
-1.02M
Net Income after Tax
FY2025Q1
YoY :
-75.57%
-0.32
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BBLG News & Events
Events Timeline
2025-06-27 (ET)
2025-06-27
07:12:16
Bone Biologics files NELL-1 protein patent application with USPTO
2025-06-26 (ET)
2025-06-26
16:20:44
Bone Biologics regains compliance with Nasdaq listing
2025-06-06 (ET)
2025-06-06
08:11:12
Bone Biologics announces 1-for-6 reverse stock split
Sign Up For More Events
Sign Up For More Events
News
8.5
06-30NewsfilterBone Biologics Announces Closing of $5.0 Million Public Offering
2.0
06-30BenzingaWhy Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket
4.5
06-27TipRanksMorning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Sign Up For More News
People Also Watch
RNAZ
Transcode Therapeutics Inc
11.590
USD
+0.74%
NAOV
Nanovibronix Inc
6.910
USD
-7.00%
CYCC
Cyclacel Pharmaceuticals Inc
8.900
USD
-4.09%
VLCN
Volcon Inc
0
USD
-15.80%
SXTP
60 Degrees Pharmaceuticals Inc
1.350
USD
0.00%
FRGT
Freight Technologies Inc
1.443
USD
-2.50%
ISPC
iSpecimen Inc
1.160
USD
+0.87%
APVO
Aptevo Therapeutics Inc
1.910
USD
-7.28%
FAQ
What is Bone Biologics Corp (BBLG) stock price today?
The current price of BBLG is 2.345 USD — it has increased 0.21 % in the last trading day.
What is Bone Biologics Corp (BBLG)'s business?
What is the price predicton of BBLG Stock?
What is Bone Biologics Corp (BBLG)'s revenue for the last quarter?
What is Bone Biologics Corp (BBLG)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bone Biologics Corp (BBLG)'s fundamentals?
How many employees does Bone Biologics Corp (BBLG). have?